Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The aim of this randomized controlled trial is to provide evidence on the efficacy and safety
of co-administered moxidectin and albendazole compared to co-administered ivermectin and
albendazole, and to assess the efficacy of the drug combinations compared to monotherapies in
adolescents aged 12-19 years against infection with T. trichiura.
The efficacy of the different treatments will be determined 14-21 days, 5-6 weeks and 3
months post-treatment. Two fecal samples will be collected at each time-point assessment. The
geometric mean based egg reduction rate (ERR) of T. trichiura egg counts will be assessed by
Kato-Katz microscopy pre-treatment and 14-21 days post-treatment.
This trial will be conducted as a school-based study on Pemba Island (Zanzibar, Tanzania).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jennifer Keiser
Collaborators:
Public Health Laboratory Ivo de Carneri Public Health Laboratory Ivo de Carneri, Chake Chake, Pemba, Zanzibar, Tanzania